Advice
Following a full submission
sevelamer (Renagel®) is not recommended for use within NHS Scotland for control of hyperphosphataemia in adult patients receiving peritoneal dialysis.
It was non-inferior to a calcium-based phosphate binder in reducing serum phosphate and was associated with a lower rate of hypercalcaemia. The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice56KB (PDF)
Medicine details
- Medicine name:
- sevelamer (Renagel)
- SMC ID:
- 423/07
- Indication:
- peritoneal dialysis in adult patients
- Pharmaceutical company
- Genzyme Therapeutics Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 December 2007